Gilead Sciences stock: BofA raised target for Gilead Sciences stock to USD 164.00
Published on 10/20/2026 at 16:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and HIV growth
- BofA raised its Gilead Sciences target from USD 162.00 to USD 164.00 on October 12, 2026.
- Second-quarter PrEP sales exceeded USD 1.0 billion after doubling year over year.
- Gilead Sciences stock costs EUR 138.02 at Lang & Schwarz on October 20, 2026 at 4:07 p.m. CEST, up 0.39 percent versus the October 19, 2026 Xetra close of EUR 137.48.
- Gilead will release third-quarter 2026 results on October 29, 2026.
Gilead Sciences (ISIN US3755581036) is trading at EUR 138.02 at Lang & Schwarz on October 20, 2026 at 4:07 p.m. CEST, up 0.39 percent versus the Xetra close of October 19, 2026. BofA Securities raised its Gilead target from USD 162.00 to USD 164.00 on October 12, 2026, while maintaining a Buy rating, as Investing.com reported. The target is 5.61 percent above the USD 155.29 Nasdaq price on October 20, 2026 at 10:18 a.m. ET.
PrEP sales pass USD 1 billion
Gilead's second-quarter 2026 PrEP sales exceeded USD 1.0 billion and doubled year over year, according to the company's earnings call carried by Yahoo Finance. The same call said more than 70 percent of users returned for reinjection at six months, while Yeztugo sales reached USD 232.00 million, up 40.00 percent sequentially.
Stock stays below yearly high
The euro quote sits EUR 4.78 below its 52-week high of EUR 142.80, a 3.35 percent gap, and above the 52-week low of EUR 98.96. Volume on the Xetra-linked quote was 6,182 shares as of October 20, 2026 at 3:31 p.m. CEST. On Nasdaq, Gilead last traded at USD 155.29 on October 20, 2026 at 10:18 a.m. ET.
Valuation and October 29 results
Gilead's market capitalization was USD 192.6 billion on October 20, 2026, while its price-to-earnings ratio was negative 58.14. The company will release third-quarter 2026 financial results on October 29, 2026 after the market closes and will hold its management webcast at 4:30 p.m. ET, according to Gilead Sciences.
Comparison with peers
Gilead Sciences: up 0.39 percent, P/E negative 58.14, market capitalization USD 192.6 billion.
Biogen (Nasdaq, USD): up 3.48 percent, P/E 42.80, market capitalization USD 35.7 billion.
Vertex Pharmaceuticals (Nasdaq, USD): up 1.86 percent, P/E 29.75, market capitalization USD 129.6 billion.
Target offers measured upside
BofA's USD 164.00 target is 5.61 percent above the current Nasdaq price, while the euro quotation remains 3.35 percent below its 52-week high. Gilead's next scheduled financial update is October 29, 2026.
The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences market data
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 4:07 p.m. CEST): EUR 138.02
- Change versus Xetra close: plus 0.39 percent
- Xetra close (October 19, 2026): EUR 137.48
- Market capitalization: USD 192.6 billion (as of October 20, 2026)
- 52-week range: EUR 98.96-EUR 142.80 (as of October 20, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
